alphascreen surefire cellular kinase assay kit (Revvity)
86
Structured Review
Revvity
alphascreen surefire cellular kinase assay kit
Alphascreen Surefire Cellular Kinase Assay Kit, supplied by Revvity, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alphascreen+surefire+cellular+kinase+assay+kit/AlphaScreen+SureFire+IKK%CE%B2+(p-Ser177%2FSer181)+Assay+Kit+-+500+Assay+Points/10__1158_slash_0008___5472__can___11___0778-91-40-53
Average 86 stars, based on 1 article reviews
Alphascreen Surefire Cellular Kinase Assay Kit, supplied by Revvity, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alphascreen+surefire+cellular+kinase+assay+kit/AlphaScreen+SureFire+IKK%CE%B2+(p-Ser177%2FSer181)+Assay+Kit+-+500+Assay+Points/10__1158_slash_0008___5472__can___11___0778-91-40-53
Average 86 stars, based on 1 article reviews
alphascreen surefire cellular kinase assay kit - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Phospho-proteomics:Article Title: STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells Article Snippet: .. Despite the prevalence of KRAS mutations in human cancers, there remain no targeted therapies for treatment.. The serine–threonine kinase STK33 has been proposed to be required for the survival of mutant KRAS-dependent cell lines, suggesting that small molecule kinase inhibitors Amplified Luminescent Proximity Homogenous Assay:Article Title: STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells Article Snippet: .. Despite the prevalence of KRAS mutations in human cancers, there remain no targeted therapies for treatment.. The serine–threonine kinase STK33 has been proposed to be required for the survival of mutant KRAS-dependent cell lines, suggesting that small molecule kinase inhibitors Kinase Assay:Article Title: STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells Article Snippet: .. Despite the prevalence of KRAS mutations in human cancers, there remain no targeted therapies for treatment.. The serine–threonine kinase STK33 has been proposed to be required for the survival of mutant KRAS-dependent cell lines, suggesting that small molecule kinase inhibitors |